{
  "query": "What are emerging biomarkers beyond PD-L1?",
  "response": "Emerging biomarkers include tumor mutational burden (TMB), microsatellite instability (MSI-H), mismatch repair deficiency (dMMR), and gene expression profiles. TMB â‰¥10 mutations/megabase shows improved response to immunotherapy regardless of PD-L1 status.",
  "attention": {
    "sources": [
      "TMB-predictive-value.pdf",
      "biomarkers-future.pdf"
    ],
    "weights": [
      0.7,
      0.3
    ],
    "patterns": [
      "sources:2",
      "outcome:success"
    ]
  },
  "outcome": "success",
  "confidence": 0.87,
  "timestamp": 1760058208796,
  "memory_type": "long-term",
  "id": "0c3777733a2c2c81727d08b6b59f8e9c35d1a3862d841adb08e235058f1f9d22"
}